INTRODUCTION
A variety of genetic/epigenetic changes within epithelial cells that initiate neoplastic transformation and promote invasive behavior and angiogenesis have been identified. In addition, signaling resulting from interactions between epithelial cells and stroma also contributes to tumor development (Bhowmick and Moses, 2005; Bissell and Radisky, 2001 ; Kalluri and Zeisberg, 2006; Red-Horse et al., 2007) . Alterations in the stroma can promote epithelial tumorigenesis (Barcellos-Hoff and Ravani, 2000; Bhowmick et al., 2004; Maffini et al., 2004) .
The stroma consists of extracellular matrix and mesenchymal cell types, which are fibroblasts and myofibroblasts, various inflammatory cells (Shojaei et al., 2008) , endothelial cells, and pericytes (Orimo and Weinberg, 2006) . Similar to transformed epithelial cells, tumor stroma may also exhibit drastic changes at the transcriptional level (Allinen et al., 2004) . Adding tumorassociated fibroblasts (TAFs) to ''initiated'' but nontumorigenic or malignant epithelial cells stimulates tumor growth and angiogenesis in vivo (Olumi et al., 1999; Orimo et al., 2005) . Orimo et al. (2005) demonstrated that SDF-1, which is upregulated in tumor fibroblasts, stimulates tumor cell proliferation and angiogenesis. TGF-b1 and HGF have been also implicated in the tumorpromoting effects of TAFs (Bhowmick et al., 2004; Kuperwasser et al., 2004) . Moreover, a recent study has indicated that gene expression signatures within the stroma can be useful prognostic predictors of breast cancer progression (Finak et al., 2008) .
Fibroblasts are thought to promote tumor growth in part through stimulation of tumor angiogenesis. One key mediator of angiogenesis is vascular endothelial growth factor A (VEGF-A) (Ferrara, 2004) . VEGF-A has been also reported to promote recruitment of bone marrow-derived cells (Grunewald et al., 2006) . Targeting VEGF-A, in combination with chemotherapy, is efficacious in treating several human tumors (Ellis and Hicklin, 2008; Ferrara and Kerbel, 2005; Kerbel, 2008) .
Platelet-derived growth factor C (PDGF-C) (Li et al., 2000) is a member of the PDGF family (Aase et al., 2002; Andrae et al., 2008; Ding et al., 2000; Fredriksson et al., 2004) . PDGF-C signaling through PDGF receptor (PDGFR) a and b homo-or heterodimers is important for the development of connective tissues and for wound healing (Andrae et al., 2008; ,
SIGNIFICANCE
Tumor-associated fibroblasts (TAFs) are active players in tumorigenesis. Here we show that TAFs may mediate resistance to antiangiogenic therapy with VEGF inhibitors. We identified platelet-derived growth factor C (PDGF-C) as a key mediator of TAF-induced angiogenesis. Blocking PDGF-C using specific antibodies reduces the growth of tumors that are resistant to anti-VEGF treatment and exhibits additive effects with anti-VEGF therapies. Hence, our data indicate that targeting stromaderived mediators such as PDGF-C can be complementary to anti-VEGF strategies.
2000; Pietras et al., 2003) . Recombinant PDGF-C stimulates angiogenesis in chick embryos and mouse corneas (Cao et al., 2002) and revascularizes ischemic tissues (Li et al., 2005) . PDGF-C has also been implicated as an autocrine growth regulator of Ewing tumor cell lines in vitro (Zwerner and May, 2002) .
Several studies have shown effects of TAFs on tumor growth and angiogenesis, but it is unclear whether there are any tumor-specific effects of TAFs. In this study, we examined TAFs isolated from two types of tumors, one of which is sensitive to anti-VEGF-A treatment and the other of which is refractory (Shojaei et al., 2007a) . Unlike normal skin fibroblasts (NSFs) or TAFs from sensitive tumors, TAFs from refractory tumors can promote in vivo growth of VEGF-sensitive tumors, even in the presence of VEGF inhibitors. Our data indicate that PDGF-C is upregulated in TAFs derived from refractory tumors and that PDGF-C, together with VEGF-A, mediates the angiogenesis induced by such TAFs in vivo. This study also demonstrates that inhibition of PDGF-C may reduce tumor angiogenesis and growth in vivo.
RESULTS

Isolation and Culture of Primary Fibroblasts from Normal Skin and Subcutaneous Tumors
TAFs were isolated from EL4 (TAF-EL4) and TIB6 (TAF-TIB6) tumors of $1000 mm 3 in size. EL4 tumors are refractory to (A) Addition of TAF-EL4, but not normal skin fibroblasts (NSFs) or TAF-TIB6, to TIB6 tumors promotes TIB6 tumor growth in anti-ragweed-treated animals (*p < 0.0001, TAF-EL4 group versus NSF group; *p < 0.015, TAF-EL4 group versus TAF-TIB6 group; #p = 0.23, NSF group versus TAF-TIB6 group). Data are presented as % change in tumor volume relative to TIB6-only control across several independent experiments (n = 3, 2, and 5, respectively).
(B) Addition of TAF-EL4, but not NSFs or TAF-TIB6, to TIB6 tumors results in increased TIB6 tumor growth in anti-VEGF mAb-treated animals (*p < 0.00005, TAF-EL4 group versus NSF group; *p < 0.0018, TAF-EL4 group versus TAF-TIB6 group; #p = 0.08, NSF group versus TAF-TIB6 group). Data reflect several independent experiments (n = 3, 2, and 6, respectively).
(C) TAF-EL4-mediated tumorigenesis contains VEGF-dependent and -independent mechanisms (*p < 0.05). Data are shown as means ± SEM.
anti-VEGF treatment, whereas TIB6 tumors are sensitive (Shojaei et al., 2007a ) (see Figure S1 available online). All primary fibroblasts (NSFs, TAF-EL4, and TAF-TIB6) exhibited spindle morphology and expressed fibroblast surface protein (FSP) ( Figures S2A and S2B ). B16F1 cells, in contrast, did not express FSP. Primary fibroblasts were also positive for a-smooth muscle actin (a-SMA) ( Figure S2C ). Moreover, NSFs and TAFs (TAF-EL4 and TAF-TIB6) were largely negative for CD31 and CD45 expression ( Figure S2D ). Less than 0.3%, 0.3%, and 1% of cells were CD31 positive, CD45 positive, or double positive respectively for all isolated fibroblasts.
TAF-EL4 Promote TIB6 Tumor Growth Even in the Presence of an Anti-VEGF Antibody Both TIB6 and TIB6-GFP were employed for recombination experiments. TIB6 and TIB6-GFP tumors exhibit similar responses to anti-VEGF treatment, although the growth rate of TIB6-GFP cells in mice is slower than that of TIB6 cells. Xenografts containing only TIB6 cells were used as a control and were implanted simultaneously with each admixture group. The addition of NSFs or TAF-TIB6 to TIB6 tumors did not alter TIB6 tumor growth (Figure 1A; Figures S3Aa and S3Ab) . In contrast, the addition of TAF-EL4 significantly enhanced TIB6 tumor growth (Figures 1A and 1C ; Figure S3Ac ). The increase in tumor mass was not due to EL4 tumor cell contamination in the fibroblast preparation, since implants containing only TAF-EL4 fibroblasts did not develop any tumors ( Figure 1C ; Figure S3Ac ). Furthermore, histological analysis revealed only a minimal number of fibroblasts ( Figure  S3Ad ), indicating that increased tumor mass reflects the growth of TIB6 tumor cells rather than TAF-EL4. Tumors from all groups displayed histology similar to control TIB6 tumors ( Figure S3Ad ).
Similar in vivo recombination experiments were performed in the presence of anti-VEGF monoclonal antibody (mAb). Neither NSFs nor TAF-TIB6 promoted TIB6 tumor growth when VEGF was inhibited (Figure 1B; Figures S3Ba and S3Bb) . In contrast, addition of TAF-EL4 induced TIB6 tumor growth in the presence of VEGF blockade (Figures 1B and 1C ; Figure S3Bc ). Admixture of TIB6 and TAF-EL4 cells generated larger tumors (Figures S3Bc and S3Bd) compared to TIB6 controls. Again, few fibroblasts were observed in the admixture tumors ( Figure S3Be ). We also used TIB6-GFP tumor cells in recombination experiments. GFP-labeled TIB6 cells were the predominant cell type within the admixture tumors ( Figure S3Bf ). TAF-EL4-only implants did not grow over the duration of the experiment ( Figure S3Bc ). These findings argue against the possibility that contaminating EL4 (GFP-negative) tumor cells contributed to the growth of admixture tumors. VEGF-dependent mechanisms are involved in TAF-EL4's ability to promote TIB6 tumor growth, since the growth of admixture tumors containing TAF-EL4 and TIB6 cells was reduced by anti-VEGF antibodies ( Figure 1C ).
TAF-EL4 Are Not Different from TAF-TIB6 in Stimulating TIB6 Cell Growth In Vitro
We cocultured TIB6 cells with NSFs, TAF-TIB6, or TAF-EL4 over a period of 3 days. TAF-EL4 did not perform better than NSFs or TAF-TIB6 in stimulating TIB6 proliferation in vitro (Figure 2A) . Similarly, no difference was observed among various fibroblasts (NSFs or TAFs) in stimulating EL4 proliferation ( Figure S4 ).
TAF-EL4 Promote Tumor Angiogenesis in the Presence of VEGF Blockade
We performed CD31 immunostaining in multiple sections from tumors with the largest and median sizes in all groups. Admixture tumors containing TAF-EL4 and TIB6 cells exhibited extensive vascular networks (Figures 2B and 2C ; Figure S5 ). The microvascular density in TIB6 and TAF-EL4 admixture tumors was 2-fold higher than that in TIB6 control tumors ( Figure 2B ). In contrast, the vascular networks in admixture tumors containing NSFs or TAF-TIB6 and TIB6 cells were similar to those of the simultaneously harvested TIB6 control tumors.
We analyzed 80 mm tumor sections by confocal microscopy and reconstructed 3D images. We measured the number of vessel branching points, number of vessel segments, segment length, total vessel length, vessel area, and vessel volume for TAF-EL4 and TIB6 admixture tumors and control TIB6 tumors. Addition of TAF-EL4 fibroblasts to TIB6 tumors led to a marked increase ($6-fold) in the number of vessel branching points ( Figure 2Cb ) and segmental vessels ($6 fold) (Figure 2Cc ) and reduced average segmental vessel length ($2-fold) (Figure 2Cd ) but increased total vessel length (>3-fold) (Figure 2Ce ), vessel area ($2.5-fold) (Figure 2Cf ), and vessel volume ($2.5-fold) (Figure 2Cg ) per field. We did not observe any difference in percent vessel coverage by PDGFRb + cells between TAF-EL4 and TIB6 admixture tumors and control TIB6 tumors (72.6% ± 1.95 and 74.5% ± 2.15, respectively). We observed, however, that many PDGFRb + cells were also dispersed throughout TIB6 tumors, whereas the majority of PDGFRb + cells within the admixture tumors were associated with vessels ( Figure 2C ).
TAFs from Anti-VEGF-Refractory Tumors Induce Angiogenesis In Vivo We injected fibroblasts in growth factor-deprived Matrigel subcutaneously into mice and allowed vessels to develop for 10 days. All primary fibroblasts (NSFs, TAF-TIB6, and TAF-EL4) expressed PDGFRb as assessed by flow cytometry (data not shown). Matrigel plugs without fibroblasts did not contain any CD31-or PDGFRb-positive cells ( Figure 3A ), suggesting little or no vessel formation and minimal invasion by host fibroblasts or pericytes. Very few vessels were observed in Matrigel plugs containing NSFs or TAF-TIB6. However, PDGFRb-positive cells were present within the implants, suggesting the survival of the implanted fibroblasts. In contrast, TAF-EL4 implants contained a well-developed microvasculature that was supported by PDGFRb-positive cells ( Figures 3A and 3C ). CD31-positive areas within Matrigel only, NSFs, TAF-TIB6, and TAF-EL4 implants amounted to 0.004%, 0.13%, 0.35%, and 10%, respectively ( Figure 3B ). TAFs from two additional tumors refractory to anti-VEGF treatment, TIB42 and TIB48 ( Figure S1 ), were able to induce angiogenesis in Matrigel plug assays ( Figures 3C and 3D ). We also isolated TAFs from GFP-positive EL4 and TIB6 tumors. However, only TAF-EL4 were able to induce angiogenesis in vivo ( Figure 3E ). No GFP-positive tumor cells were present in the implants, whereas such cells were readily observed in the positive controls. Similar experiments were also carried out using TAF-TIB48 from TIB48-GFP tumors. Again, TAF-TIB48 alone induced angiogenesis in vivo without contaminating TIB48-GFP cells ( Figure 3D , left panel). These data indicate that the angiogenesis we observed in TAF-EL4 or TAF-TIB48 implants was due to signals from TAF-EL4 or TAF-TIB48 cells, not from contaminating tumor cells.
The onset of angiogenesis involves invasion of tip cells, followed by stalk endothelial cells, to populate avascular areas (Davis and Senger, 2005; Gerhardt and Betsholtz, 2005) . Close examination of vessels within TAF-EL4 implants at high magnification (403) revealed that many CD31-positive endothelial cells possessed tip-cell-like phenotypes (i.e., multiple cytoplasmic extensions) ( Figure 3F ).
TAF-EL4 Express Higher Levels of VEGF-A, but Not SDF-1, In Vivo
We measured VEGF concentrations in NSFs, TAF-TIB6, and TAF-EL4 both in vitro and in vivo. TAF-TIB6 and TAF-EL4 secreted higher levels of VEGF than NSFs in vitro ( Figure 4A ). However, VEGF levels in TAF-EL4 or TAF-TIB6 conditioned media were similar. We then measured VEGF from fibroblast implant lysates. Unlike the in vitro data, VEGF levels were highest in the TAF-EL4 groups ( Figure 4B ). TAF-TIB6 in vivo implants contained the lowest amounts of VEGF ($50 pg/ml). These data suggest that VEGF might partially account for the ability of TAF-EL4 to induce angiogenesis. However, NSF implants, which exhibit only 2-fold lower VEGF production, did not induce any microvascular sprouting, suggesting that one or more additional factors produced by TAF-EL4 cooperate with VEGF to stimulate angiogenesis.
It has been reported that TAFs promote tumor growth via upregulation of SDF-1 (Orimo et al., 2005) . However, we found reduced levels of SDF-1 in TAF-EL4 and TAF-TIB6 implants compared to NSF implants ( Figure 4C ), suggesting that the angiogenesis observed in TAF-EL4 implants is not mediated by SDF-1.
PDGF-C Is Upregulated in TAFs from Refractory Tumors
We compared gene expression profiles of TAFs from resistant versus sensitive tumors by microarray analysis. Unsupervised clustering analysis of genes that exhibited statistically significant changes revealed a pattern that clearly separated TAFs of resistant tumors (TAF-EL4, TAF-TIB42, and TAF-TIB48) from NSFs and TAF-TIB6 ( Figure 5A ). Microarray analysis (and subsequent TaqMan analysis) revealed that PDGF-C, Angptl2, HOX-A10 and A7, and COX-2 were among the upregulated genes in TAFs from resistant tumors. The complete data set is available at the NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) with the accession number GSE13549.
We focused our analysis on secreted or cell surface proteins. Among the genes that demonstrated reproducible changes across multiple probes included in the microarray chip, PDGF-C was consistently upregulated in TAFs from three different resistant tumors. While all TAFs exhibited higher PDGF-C expression than NSFs did, expression of PDGF-C was highest in TAFs from resistant tumors ( Figure 5B) . Surprisingly, we observed a downregulation of SDF-1 in TAFs from refractory tumors ( Figure 5C ).
We also dissociated TIB6 and EL4 tumors and flow-sorted cells into four different populations: tumor cells (GFP + ), enriched
, and bone marrow-derived cells (including resident macrophages) (GFP
. TaqMan analysis on such freshly isolated cells indicated that all cell types within TIB6 tumors had minimal PDGF-C expression ( Figure 5D ). Cells from EL4 tumors exhibited elevated levels of PDGF-C compared to those in TIB6 tumors, the highest expression being observed in enriched fibroblasts.
VEGF and PDGF-C Are Required for TAF-Induced Angiogenesis In Vivo
To determine whether the angiogenesis induced by TAF-EL4 requires VEGF-A, we treated the animals harboring the implants with anti-VEGF mAb for 30 days. We observed some vessels in TAF-EL4 implants treated with anti-VEGF. However, when compared to the control antibody-treated group, vascular densities were markedly reduced ( Figure 6A ; Figure S6 ), indicating that VEGF is required for the full angiogenic response.
We next asked whether PDGF-C is required for TAF-EL4-induced angiogenesis. We used a neutralizing affinity-purified anti-mPDGF-C IgG. Western blot analysis demonstrated that this antibody interacted strongly with mouse or human PDGF-C but had no detectable interaction with PDGF-A, PDGF-B, PDGF-D, or VEGF-A ( Figure S7 ). In addition, the antibody specifically neutralized PDGF-C-induced endothelial cell migration (see below).
TAF-EL4 fibroblasts mixed with PBS, goat IgG, or anti-PDGF-C IgG were implanted subcutaneously. Addition of anti-PDGF-C IgG to TAF-EL4 implants significantly delayed the angiogenic response ( Figures 6B and 6C ). There was >6-fold reduction in normalized vascular density in TAF-EL4 implants containing anti-PDGF-C antibody as compared to TAF-EL4 implants containing goat IgG ( Figure 6C ). The requirement for PDGF-C in TAF-induced angiogenesis was not limited to TAF-EL4, since similar results were obtained with TAF-TIB42 cells (data not (D) TAF-TIB48 are able to induce angiogenesis in vivo. As a positive control, TAF-TIB48 were mixed with TIB48-GFP tumor cells prior to implantation (right panel). Scale bars = 100 mm. (E) TAF-EL4-induced angiogenesis does not result from EL4 tumor cell contamination. TAF-TIB6 and TAF-EL4 fibroblasts were isolated from TIB6-GFP and EL4-GFP tumors, respectively. No GFP-positive tumor cells were observed in either TAF-TIB6-or TAF-EL4-only implants. GFP-positive tumor cells were used as positive control. Scale bars = 100 mm. (F) Cells with tip-cell-like phenotypes were observed in TAF-EL4-only implants. Scale bars = 50 mm.
shown). Incubation of TAF-EL4 or TAF-TIB42 with anti-PDGF-C did not affect TAF viability ( Figure S8 ), indicating that the reduction in vascular density resulting from anti-PDGF-C was not due to impaired TAF viability.
Conversely, we added recombinant PDGF-C to nonangiogenic TAF-TIB6 in Matrigel plugs. While TAF-TIB6 alone were unable to induce angiogenesis, addition of PDGF-C ($3.3 mg) led to an increase in vascular density compared to control ( Figures 6D  and 6E ). SDF-1 ($3.3 mg), a cytokine that has been shown to induce angiogenesis in other biological settings, did not induce such effects under the conditions tested ( Figures 6D and 6E ).
Anti-PDGF-C Antibodies Suppress the Growth of EL4 and TAF-EL4 Admixture Tumors and Are Additive with Anti-VEGF Antibodies Addition of TAF-EL4 to TIB6-GFP tumor cells promoted TIB6 tumor growth in both anti-ragweed-and anti-VEGF-treated groups ( Figure 7A ). Single-agent treatment of admixture tumors with anti-PDGF-C IgG resulted in $63% growth inhibition at day 20 relative to goat IgG ( Figure 7A ; Figure S9 ). Moreover, combination of anti-PDGF-C and anti-VEGF antibodies further reduced the growth of admixture tumors compared to monotherapy with anti-VEGF mAb. By day 34, the combination resulted in $74% growth inhibition compared to anti-VEGF alone. We next tested the efficacy of anti-PDGF-C antibodies on growth of EL4 tumors. Anti-PDGF-C IgG reduced the growth of EL4 tumors by $32% (Figures  7Ba and 7Bd) . A comparable degree of inhibition ($37%) was achieved using anti-VEGF mAb (Figures 7Bb and 7Bd) . Greater inhibition ($62%) was observed in animals treated with both anti-PDGF-C and anti-VEGF antibodies (Figures 7Bc and 7Bd) .
In contrast, anti-PDGF-C IgG had no effect on TIB6 tumor growth (Figure 7Ca ), whereas anti-VEGF mAb resulted in a dramatic inhibition (Figures 7Cb and 7Cd) . These findings are consistent with the minimal expression of PDGF-C in TAFs or other cell fractions from TIB6 tumors ( Figure 5D ).
PDGF-C Induces Migration of
Endothelial Cells, but Not of CD11b +
Gr1
+ Cells
To identify the potential target (or targets) of PDGF-C, we analyzed the expression levels of PDGFRa and b in different cell populations within TIB6 and EL4 tumors. In addition to PDGF-C, PDGFRa and b were upregulated in enriched fibroblasts, endothelial cells, and bone marrow cells within EL4 tumors ( Figure 8A ). Since previous studies (Shojaei et al., 2007a) tumor-bearing mice expressed very low levels of PDGF-C receptors ( Figure 8A ). Accordingly, PDGF-C did not induce the migration of myeloid cells ( Figure 8B ). However, SDF-1 strongly induced migration of these cells. Moreover, PDGF-C did not upregulate any proangiogenic genes tested PLGF, HGF, FGF2, Angpt2, Angptl1 and 2, MMP9, and MMP13) in CD11b + Gr1 + cells (data not shown). While mesenchymal cells are PDGF-C's primary target, PDGF-C can also induce migration of mouse endothelial progenitors and human endothelial cells (Li et al., 2005) . Endothelial cells within EL4 tumors expressed PDGFRs, raising the possibility that the PDGF-C-mediated angiogenesis we observed could be explained at least in part by its direct effect on endothelial cells. We isolated and cultured primary mouse endothelial cells (mECs) from normal lungs. mECs expressed mRNAs for PDGFRa and b (Figure 8A ), VEGFRs, and other endothelial cell specific markers (Figures S10 and S11 ). VEGF-A induced mEC migration in vitro (Figure 8Ca ). PDGF-C induced migration of mECs comparable to VEGF (Figure 8Cb ). Anti-PDGF-C IgG specifically blocked mEC migration induced by PDGF-C, whereas goat IgG had no inhibitory effects.
DISCUSSION
We chose murine lymphoma models for our study because tumor-free TAFs could be easily isolated from these tumors, providing a suitable and reproducible experimental system. TAF-EL4, but not TAF-TIB6, were able to stimulate the in vivo growth of the anti-VEGF-sensitive TIB6 tumor, suggesting that signals from tumor cells can regulate TAF tumorigenic properties. Furthermore, TAF-EL4 can also stimulate TIB6 tumor growth even when VEGF signaling is inhibited, suggesting that TAFs can modulate tumors' responses to anti-VEGF therapy. Our analysis revealed both VEGF-dependent and -independent mechanisms for TAF-EL4-mediated tumor promotion. Other studies investigating tumor resistance/refractoriness to antiangiogenic therapies with VEGF blockers have identified additional potential mechanisms, including expression of alternative angiogenic factors (Bergers and Hanahan, 2008; Fischer et al., 2007) , selection of hypoxia-resistant tumor cells (Yu et al., 2002) , and recruitment of myeloid cells (Shojaei et al., 2007a) .
TAFs have been reported to upregulate CXCL14 and SDF-1 (CXCL12), which may directly stimulate tumor cell proliferation (Allinen et al., 2004; Orimo et al., 2005) . However, in our study, we did not find any evidence that TAF-EL4 potentiate tumor growth by promoting tumor cell proliferation. Rather, TAF-EL4 were able to stimulate tumor angiogenesis. Interestingly, in admixture tumors containing both TAF-EL4 and TIB6 cells, we also observed a close association between PDGFRb-positive cells and blood vessels, while in TIB6 control tumors, some PDGFRb-positive cells were associated with vessels and some were dispersed throughout the tumor. This observation suggests that TAF-EL4, which also express PDGFRb, may be able to support the survival and/or stability of newly formed vessels when VEGF is inhibited. Furthermore, TAF-EL4 or TAFs isolated from other resistant tumors were able to induce angiogenesis in vivo, demonstrating that the ability to induce such activity is maintained regardless of the presence of tumor cells. These data suggest that epigenetic and/or genetic modulations may have occurred in such TAFs. In this context, previous studies have reported genetic alterations in tumor-associated stromal cells (Pelham et al., 2006) . In other cases, epigenetic modulations may be involved (Qiu et al., 2008) . However, we did not observe any statistically significant copy number gains or losses in any fibroblasts used in this study ( Figure S12 ). VEGF-A is a major regulator of angiogenesis and is expressed by fibroblasts (Dong et al., 2004) . Therefore, it is possible that the tumor-promoting effects of TAF-EL4 in animals treated with anti-VEGF result at least in part from upregulation of VEGF-A. In vivo, VEGF-A concentrations were highest in TAF-EL4 implants. VEGF was indeed important for angiogenesis, since treatment with anti-VEGF antibodies significantly reduced CD31-positive areas in such implants. However, the concentrations of VEGF in TAF-EL4 implants were low and only about 2-fold higher than that in NSF implants, which did not trigger any angiogenesis. This observation, together with the finding that 5 mg/ml of VEGF alone did not induce angiogenesis in the Matrigel plug assay over the same time period (data not shown), suggests that one or more other factors from TAF-EL4 synergize with VEGF. SDF-1 has been characterized as a mediator of TAF-induced tumor angiogenesis (Orimo et al., 2005) . However, in our system SDF-1 does not appear to be involved, highlighting the complexity and multiplicity of pathways that regulate angiogenesis.
Our analysis shows that fibroblasts from EL4 tumors upregulate PDGF-C compared to fibroblasts from TIB6 tumors. The largest difference was observed when comparing freshly isolated fibroblasts from EL4 and TIB6 tumors. Among different cell populations within EL4 tumors, fibroblasts expressed the highest level of PDGF-C mRNA. Moreover, PDGFRa and b were upregulated in fibroblasts, endothelial cells, and bone marrow-derived cells from EL4 tumors, suggesting possible autocrine and paracrine effects of PDGF-C during EL4 tumor progression. The receptors for PDGF-C, PDGFRa and b, (Cao et al., 2002) , have been detected in various cell types including endothelial precursor cells, tumor endothelial cells, pericytes, and fibroblasts (Bergers et al., 2003; Dong et al., 2004; Marx et al., 1994; Pietras et al., 2003; Rolny et al., 2006) . Our data point to tumor-specific upregulation of PDGFRa and b in TAFs, endothelial cells, and bone marrow-derived cells. by VEGF-A. These findings are also consistent with other studies reporting direct chemotactic effects of PDGF-C on human endothelial cells (Li et al., 2005) . Together, these observations support the hypothesis that PDGF-C can directly act on endothelial cells, providing a rationale for its ability to promote angiogenesis.
Intriguingly, upregulation of PDGF-C occurs in several human tumors (Lokker et al., 2002; Ostman and Heldin, 2001; Zwerner and May, 2001) , including pancreatic carcinomas (Genentech Gene Logic analysis, data not shown). Pancreatic cancers are enriched in fibroblastic stroma and have shown a very limited response to most therapies, including combinations of anti-VEGF antibodies and chemotherapy (Ellis and Hicklin, 2008; Ferrara and Kerbel, 2005; Kerbel, 2008) . Ectopic expression of PDGF-C in mice induces fibrosis and carcinogenesis (Campbell et al., 2005) . PDGF-C may also act directly on tumor cells to promote their survival and/or proliferation (Lokker et al., 2002) . EL4 tumor cells express PDGFRa. However, PDGF-C did not stimulate EL4 tumor cell proliferation or migration in vitro ( Figure S13 ).
In this study, we demonstrate that an anti-PDGF-C neutralizing antibody can inhibit the angiogenic effects of TAFs isolated from tumors refractory to anti-VEGF treatment. A combination (Ca) VEGF stimulates mEC migration (*p < 0.02, VEGF versus control media). Anti-VEGF mAb blocks VEGF-mediated mEC migration (*p < 0.004), whereas anti-PDGF-C antibodies do not (#p = 0.2).
(Cb) PDGF-C induces mEC migration (*p < 0.03, PDGF-C versus control). Anti-PDGF-C antibodies block PDGF-C-mediated mEC migration (*p < 0.036), whereas control IgGs have no effect (#p = 0.4). Data are shown as means ± SEM.
therapy utilizing both anti-PDGF-C and anti-VEGF antibodies was more effective than anti-VEGF treatment alone. However, this combination did not completely block tumor growth, suggesting that additional mechanisms are involved. Indeed, we have previously reported that CD11b + Gr1 + myeloid cells stimulate tumor angiogenesis via another secreted protein, Bv8, and contribute to tumor resistance to anti-VEGF treatment (Shojaei et al., 2007a (Shojaei et al., , 2007b . These findings suggest that, within the same tumor, multiple molecular and cellular mechanisms resulting in VEGF-independent angiogenesis may coexist. While our analysis here focused on PDGF-C, array data identified additional potential candidates such as Angptl2, which has been implicated in angiogenesis (Oike et al., 2004) . Whether Angptl2 plays a role in tumor refractoriness to anti-VEGF therapy remains to be determined. Previous studies suggested that a combination of VEGF antagonists with PDGFR inhibitors, such as imatinib, might be a particularly effective anticancer strategy (Bergers et al., 2003; Erber et al., 2004; Jo et al., 2006) . However, recent studies suggest that such an approach is associated in some cases with marked toxicity (Hainsworth et al., 2007) . It is tempting to speculate that a combination therapy utilizing a more selective inhibition of the PDGF axis, such as that achieved by targeting PDGF-C, may offer some advantages, at least in some circumstances.
In conclusion, we have demonstrated that activation of VEGFindependent proangiogenic programs in TAFs is tumor specific. Once activated by the tumor environment, TAFs can maintain their ability to induce angiogenesis independent of tumor cells, thus suggesting an irreversible process. We have also identified PDGF-C as an important mediator of TAF-induced angiogenesis and tumorigenesis in vivo.
EXPERIMENTAL PROCEDURES
Cell Lines
The EL4, TIB6 (J558), TIB42 (R1.1), and TIB48 (BW5147.G.1.4) cell lines were purchased from the American Type Culture Collection and cultured in DMEM supplemented with 10% fetal bovine serum.
Isolation and Culture of Normal or Tumor-Associated Fibroblasts
Normal skin fibroblasts (NSFs) were isolated from dorsal skin of beige/nude/ xid mice. Tumor-associated fibroblasts (TAFs) were isolated from tumors reaching $1000 mm 3 in size from the same genetic background. To generate TAFs, 1 3 10 6 cells were injected subcutaneously into the dorsal flank of 8-to 10-week-old beige/nude/xid mice. Tissues were digested with RPMI with 0.037% hyaluronidase (Sigma), 1 mg/ml collagenase/dispase (Roche), 10% FBS, and antibiotics for 1-2 hr at 37 C. Dissociated cells were filtered through both 100 mm and 40 mm filters. Washed filtrates were plated onto 1% gelatincoated plates and cultured in 10% FBS-containing medium in an atmosphere of 3% O 2 . Suspension tumor cells were removed after vigorous washing or flow sorting. All NSFs and TAFs used in this study had undergone fewer than ten population doublings in culture.
TaqMan Analysis
All TaqMan primers used were from Applied Biosystems. All analyses were carried out on a standard ABI 7500 machine using the SuperScript III Platinum One-Step qRT-PCR Kit (Invitrogen) according to the manufacturer's recommended protocols.
Antibodies
Anti-VEGF-A mAb G6-31 was derived from human Fab phage libraries (Liang et al., 2006) . The variable domains were grafted into the murine IgG2a constant domain. The ability of mAb G6-31 to potently neutralize mouse or human VEGF-A in vitro and in vivo has been previously documented (Gerber et al., 2007; Yu et al., 2008) . Anti-ragweed mAb was used as a control for mAb G6-31 (Liang et al., 2006) . Neutralizing, affinity-purified anti-mPDGF-C goat IgG was purchased from R&D Systems (AF1447). Goat IgG was used as a control.
Western Blot
Human and murine PDGF-C (R&D Systems), murine VEGF-A 164 (R&D Systems), human VEGF-A 165 (Genentech, Inc.), murine PDGF-A and PDGF-B (Antigenix America Inc.), and human PDGF-D (R&D Systems) were loaded into duplicate 4%-20% SDS-PAGE (Invitrogen). All proteins were purified from E. coli, except murine VEGF-A, which was expressed in insect cells. Five hundred nanograms of each protein was loaded. PVDF membranes were then incubated overnight with 0.2 mg/ml anti-mouse PDGF-C IgG (R&D Systems, AF1447) or with 10 mg/ml mAb G6-31. The blots were incubated with ImmunoPure HRP-conjugated rabbit anti-goat IgG or goat anti-mouse IgG (Pierce) at a dilution of 1:10,000 and detected using a western blotting detection system (GE Healthcare Bio-Science).
Immunohistochemistry and Flow Cytometry
Live NSFs and TAFs were stained with FITC-or APC-conjugated anti-CD45 and anti-CD31 antibodies (BD Pharmingen). For a-SMA staining, cells were fixed in 4% PFA prior to staining with FITC-conjugated a-SMA (Sigma). The percentage of cells expressing CD45, CD31, and a-SMA was quantified using flow cytometry.
In Vivo Recombination Experiments
Animal studies were approved by the Genentech animal care committee and performed according to regulatory standards. 8 3 10 5 TIB6 tumor cells in growth factor-deprived Matrigel (BD Biosciences) or admixtures of TIB6 cells and NSFs or TAFs at a ratio of 1:2.5 were injected subcutaneously in 8-to 10-week-old beige/nude/xid mice. Treatment with anti-ragweed or anti-VEGF-A mAb G6-31 was initiated 48 hr after cell inoculation and was administered once a week thereafter at a dose of 5 mg/kg. In vivo recombination experiments were divided into three groups using NSFs, TAF-TIB6, or TAF-EL4. Each group contained both control and anti-VEGF-treated arms.
In Vivo Matrigel Plug Assay NSFs or TAFs were mixed with growth factor-deprived Matrigel and injected subcutaneously in beige/nude/xid mice at a density of $2 3 10 6 cells/100 ml of Matrigel. The Matrigel implants were cleared, harvested, and cryofrozen at day 8 for detection of VEGF and SDF-1 levels and at day 10 for vascular staining. In some cases, fibroblasts were mixed with control solutions, goat IgGs (3.3 mg), anti-PDGF-C IgG (3.3 mg), recombinant PDGF-C (3.3 mg), or SDF-1 (3.3 mg) prior to injection. Neutralizing anti-mouse PDGF-C IgG (AF1447) and recombinant PDGF-C and SDF-1 were from R&D Systems. PDGF-C stock solution contained 4 mM HCl. All control experiments for PDGF-C contained the same amount of diluted HCl.
Coculture Studies
NSFs or TAFs were plated onto 1% gelatin-coated 24-well plates and cultured under 3% O 2 . TIB6 and EL4-GFP cells were added to the fibroblast cultures, which were in 1% FCS, the next day. The number of TIB6 or EL4 cells after 3 days of coculture was counted using a Z2 particle counter and size analyzer (Beckman).
Vascular Staining in Cryofrozen Samples
Cryofrozen tumor tissues or Matrigel plugs were sectioned at 80 mm thickness. Each slide contained two 80 mm sections that were at least 1000 mm apart in the tumor samples. Slides were stained with primary antibodies including hamster anti-mouse CD31 antibody (Chemicon), rat anti-mouse PDGFRb antibody (eBioscience), or rabbit anti-mouse collagen IV antibody (Cosmo Bio Co., Ltd.). Samples were then stained with secondary antibodies including FITC-, Cy3-, or Cy5-conjugated goat anti-hamster or anti-rat from Jackson ImmunoResearch.
Vascular Density Quantification
Vascular density was assessed by measuring CD31 + areas per field using ImageJ software. To quantify vascular branching points, segmental length, vessel length, vessel area, and vessel volume, 3D confocal images of the vascular network were reconstructed (80 mm in depth) using FilamentTracer and quantified using Imaris software. Each intersection of two or more branches was identified automatically for quantifying the number of branching points and vessel segments between intersections.
VEGF and SDF-1 Assays VEGF concentrations were measured using a mouse VEGF ELISA kit (R&D Systems) according to the manufacturer's instructions. SDF-1 concentrations were determined by ELISA (Genentech).
Microarray Experiments and Analysis
Microarray experiments were performed using Agilent Whole Mouse Genome expression arrays using Agilent-recommended protocols. Universal mouse reference RNA was applied in each array (Stratagene). Three replicates were prepared for each sample. Raw ratio values were log2 transformed, and a Cyber t test (Baldi and Long, 2001 ) was performed to identify probe sets differentially expressed between all sensitive and all resistant samples.
In Vivo Tumor Growth Studies with Anti-PDGF-C or Anti-VEGF Antibodies Recombination experiments using TAF-EL4 and TIB6-GFP cells were carried out as described above. 1 3 10 6 EL4 or TIB6 cells were injected subcutaneously. All treatments were initiated at day 2. Thirty micrograms of anti-PDGF-C neutralizing IgG or control goat IgGs in 50 ml solutions was administrated every 2 days intratumorally, given the limited availability of such antibody. Anti-VEGF mAb or anti-ragweed antibodies were administered every 6 days at 5 mg/kg intraperitoneally.
Expression Analysis in Cells within TIB6 or EL4 Tumors and in Primary Mouse Endothelial Cells TIB6-GFP and EL4-GFP tumors ($1000 mm 3 ; n = 5 each) were dissociated and sorted by flow cytometry into four populations of cells based on expression of GFP, CD31, and CD45. APC or FITC-conjugated anti-CD31 or CD45 antibodies were from BD Pharmingen. Primary mouse endothelial cells were isolated from normal BALB/c mouse lungs using a MACS Cell Separation kit (Miltenyi Biotec) according to the manufacturer's protocol. CD45 beads were used for negative selection, while CD31-FITC and anti-FITC beads were used for positive selection. Cells were cultured in EGM-2MV growth medium (Lonza) and were sorted again for CD31 expression. Postsorting analysis revealed that >99.5% of cells were CD31 + . Gene expression analysis was determined by TaqMan as described above.
In Vitro Migration Assays
Mouse endothelial and EL4 cells were exposed to EBM or DMEM media with 0.1% BSA and then plated onto either fibronectin-coated or noncoated upper chambers (8 mm and 5 mm pore size, respectively) of migration assay plates (BD Biosciences). CD11b + Gr1 + cells were isolated from the bone marrow of naive or EL4 tumor-bearing mice by flow cytometry. FITC-and PE-conjugated anti-Gr1 and anti-CD11b antibodies were from BD Biosciences. Noncoated inserts with 5 mm pore size were used for the experiment. Endothelial cells that migrated across the upper chamber after 6 hr of cytokine stimulation were stained with Sytox green nucleic acid stain (Invitrogen) and imaged. Nuclei numbers were counted using ImageJ software. Numbers of migrated EL4 and myeloid cells were determined using a Z2 particle counter and size analyzer. Cytokines or serum were added to the bottom chambers; antibodies or control IgGs were added to both chambers.
Array CGH Agilent Mouse Genome CGH Microarray 244A was used for array CGH analysis according to Agilent-recommended protocols. Normal genomic DNA was used as the control channel on all arrays (strain 000664, The Jackson Laboratory). The resulting Agilent expression ratios were log2 transformed, centered to a median of zero, and segmented using GLAD (Hupe et al., 2004) . All statistical analysis was performed using Partek software (Partek Inc., version 6.08.0414).
Statistical Analysis
Statistical analysis was performed by t test except where otherwise noted in figure legends or elsewhere in the Experimental Procedures.
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